- Home
- SUPN vs LILAK Comparison
SUPN vs LILAK Comparison
Compare SUPN & LILAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPN
- LILAK
- Stock Information
- Founded
- SUPN 2005
- LILAK 2017
- Country
- SUPN United States
- LILAK Bermuda
- Employees
- SUPN N/A
- LILAK N/A
- Industry
- SUPN Biotechnology: Pharmaceutical Preparations
- LILAK Cable & Other Pay Television Services
- Sector
- SUPN Health Care
- LILAK Telecommunications
- Exchange
- SUPN Nasdaq
- LILAK Nasdaq
- Market Cap
- SUPN 1.7B
- LILAK 1.4B
- IPO Year
- SUPN 2012
- LILAK N/A
- Fundamental
- Price
- SUPN $32.90
- LILAK $6.51
- Analyst Decision
- SUPN Hold
- LILAK Buy
- Analyst Count
- SUPN 2
- LILAK 3
- Target Price
- SUPN $36.00
- LILAK $10.27
- AVG Volume (30 Days)
- SUPN 787.3K
- LILAK 855.5K
- Earning Date
- SUPN 05-07-2025
- LILAK 05-06-2025
- Dividend Yield
- SUPN N/A
- LILAK N/A
- EPS Growth
- SUPN 6500.00
- LILAK N/A
- EPS
- SUPN 1.32
- LILAK N/A
- Revenue
- SUPN $661,817,000.00
- LILAK $4,456,900,000.00
- Revenue This Year
- SUPN N/A
- LILAK $3.68
- Revenue Next Year
- SUPN $8.67
- LILAK $3.55
- P/E Ratio
- SUPN $24.90
- LILAK N/A
- Revenue Growth
- SUPN 8.94
- LILAK N/A
- 52 Week Low
- SUPN $25.53
- LILAK $5.88
- 52 Week High
- SUPN $40.28
- LILAK $10.93
- Technical
- Relative Strength Index (RSI)
- SUPN 46.17
- LILAK 43.82
- Support Level
- SUPN $31.69
- LILAK $6.61
- Resistance Level
- SUPN $32.90
- LILAK $7.02
- Average True Range (ATR)
- SUPN 0.96
- LILAK 0.22
- MACD
- SUPN 0.29
- LILAK -0.02
- Stochastic Oscillator
- SUPN 89.25
- LILAK 15.65
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About LILAK Liberty Latin America Ltd. Class C
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico, and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.